Tubulis

Drug Discovery · Planegg-Martinsried, Germany · Founded 2012 · Privately Held (backing)

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. Tubulis is based in Planegg-Martinsried, Germany and was founded in 2012. It was valued at $5.8 billion at a merger or acquisition in Apr 2026, the last priced event on record. It has raised $618 million across 1 recorded round; the latest was a $361 million Series C in Oct 2025.

PMV mark · valuation
$5.8B
Oct 2026
Priced at
a merger or acquisition
Apr 2026
Total raised
$618.5M
Last round
Later Stage VC (Series C)
Oct 2025

Leadership

5
+ 17 more people (board, observers, advisors) · free account shows everyone

Membership and data by Private Market View

Who runs Tubulis

22 people are listed on the Tubulis team: 7 executives, 7 board members and 8 advisors and observers, including Jonas Helma-Smets (Chief Scientific Officer) and Halley Gilbert (Chief Legal Officer). 21 of them have a verified direct contact on file.

Free account
More of Tubulis with a free account
  • ·The complete investor list: 26 names
  • ·Everyone on the team, board and advisors included
  • ·Watch Tubulis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Contact database
Verified contact details, revealed on demand

21 of the people at Tubulis have a verified contact on file. Plus members reveal 10 contacts a month, Pro members 200.

Unlock contact reveals

Membership and data by Private Market View